78,520 Shares in Boston Scientific Corporation $BSX Acquired by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 78,520 shares of the medical equipment provider's stock, valued at approximately $3,351,000.

Other large investors have also modified their holdings of the company. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter worth $26,000. Sfam LLC purchased a new position in Boston Scientific during the 4th quarter worth $29,000. Finally, Cresta Advisors Ltd. acquired a new position in Boston Scientific in the fourth quarter valued at $33,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent research reports. Piper Sandler reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Royal Bank Of Canada cut their price target on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, July 30th. Leerink Partners set a $60.00 price target on Boston Scientific in a report on Thursday, July 30th. Weiss Ratings cut shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Tuesday, July 7th. Finally, Argus restated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $71.62.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company's stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 over the last quarter. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Stock Up 0.3%

Boston Scientific stock opened at $46.82 on Friday. The firm has a market capitalization of $67.85 billion, a price-to-earnings ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The stock's fifty day moving average is $46.56 and its two-hundred day moving average is $56.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source